AUSTIN, Texas, Oct. 1, 2019 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) announced that the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ARIES® MRSA Assay. The assay is an integrated, real-time, polymerase chain reaction (PCR) based, qualitative, in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA)... Read more
Basel, 30 September 2019 FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vasculitis in children are rare and associated with severe,... Read more
PERTH, Australia and BILLERICA, Mass., Sept. 20, 2019 /PRNewswire/ — Murdoch University and Bruker (Nasdaq: BRKR) today announced a strategic collaboration that will help transform the prevention and diagnosis of disease and personalised health around the world. The Murdoch-Bruker collaboration will play a key role within the Australian National Phenome Centre (ANPC)1, the international centre... Read more
Basel, 20 September 2019 FDA approves cobas Babesia, Roche’s first whole blood test for donor screening Roche is dedicated to helping save patients’ lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infection can be fatal in patients receiving blood transfusions from infected... Read more
Basel, 18 September 2019 FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal... Read more
New LPC 500-Avio 500 ICP-OES Oils solution streamlines workflows and delivers accurate results in under 60 seconds WHAT: PerkinElmer Inc. has today announced its new LPC 500™ Liquid Particle Counter (LPC 500) platform which will couple with PerkinElmer’s existing Avio® 500 ICP-OES Oils system to join, for the first time, particle counting and sizing as well... Read more
Basel, 16 September 2019 Roche receives FDA clearance for cobas pro integrated solutions designed to help labs deliver faster results to patients cobas pro integrated solutions improves productivity in the lab and enhances reliability and turnaround times in delivering results to patients By simplifying operations in the lab, Roche is in-turn helping physicians provide evidence-based... Read more
“X-ray – the world’s oldest form of medical imaging – just got a whole lot smarter, and soon, the rest of our offerings will too,” says Kieran Murphy, President & CEO, GE Healthcare. “GE Healthcare is leading the way in the creation of AI applications for diagnostic imaging and taking what was once a promise... Read more
RYE BROOK, N.Y.–(BUSINESS WIRE)–Aug. 27, 2019– Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, announced today that its Senior Director of Investor Relations, Matt Latino, will participate in investor meetings at the Seaport Global 2019 Energy and Industrials Conference at the JW Marriott Hotel... Read more
Basel, 16 August 2019 FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche’s first FDA-approved tumour-agnostic medicine Roche (SIX: RO, ROG;... Read more